Dr. Arthur J Blume , President and Chief_Operating_Officer of DGI , commented : I welcome the opportunity to collaborate with a partner having such strong scientific capabilities as Novo Nordisk.This agreement signals validation by a major pharmaceutical company of the new approach DGI is pioneering for small molecule drug discovery".
DGI BioTechnologies LLC is majority-owned by New_Brunswick Scientific Co. , Inc , New_Brunswick , New_Jersey.DGI intends to license potential drug candidates , either before or after pre-clinical development at DGI , to pharmaceutical and biotechnological companies.DGI expects that its drug discovery technology will result in the identification of novel therapeutic agents for a wide range of diseases.
Arthur J. Blume, Ph.D., is the Founder, President and Chief Executive Officer of DGI BioTechnologies.Dr Blume has been involved in drug discovery for over 30 years.He. has been a player in the pharmaceutical industry including stints as Chief Operating Officer at GeneLogic and as Group Manager and Research Fellow at Lederle Laboratories where his work focused on research and drug discovery for CNS related pathologies.He was one of the founding members of the Roche Institute of Molecular Biology where he specialized in transmembrane signaling through opiate and adenosine G protein coupled receptors.Dr. Blume received his PhD in 1968 and did post-doctoral work at the NIH.
Analytical Edge was founded by Arthur Blume, Ph.D. and Jeffrey Blume, Ph.D.
Arthur Blume, the CEO and President, has more than 35 years of experience in biotechnology and pharmaceutical research and development.Dr. Blume helped to co-found two biotechnology companies, Gene Logic Inc. (NASDAQ: GLGC) and DGI Biotechnologies (now Antyra Inc.), a drug development venture which partnered with Novo Nordisk.
Previously, Dr. Blume spent eight years with Lederle Labs/American Cyanamid and, before that, 14 years with the Roche Institute of Molecular Biology, the research affiliate of F. Hoffmann-LaRoche & Co.Prior to joining the Roche Institute, Dr. Blume spent four years in the Laboratory for Biochemical Genetics at NIH.His primary research interests have been in the field of neurobiology.
He received his Ph.D. in molecular biology from Syracuse University in 1968.
Likelihood methodology for measuring statistical evidence provides a low cost solution to this problem because it maximizes a clinical triae's efficiency, flexibility, and accuracy from a statistical perspective," said Analytical Edge CEO Arthur Blume.
We look forward to working with Arthur and Jeff as well as their colleagues at Brown in addressing this important challenge."
New Brunswick Scientific Co., Inc. Acquires Inceltech
New Brunswick Scientific Co., Inc. Names Dr. Arthur Blume CEO of DGI BioTechologiesNew Brunswick Scientific Co., Inc.
DR. ARTHUR BLUME CEO OF DGI BIOTECHNOLOGIES Edison, New Jersey, February 7, 2000 -- New Brunswick Scientific Co., Inc. (NBS) (Nasdaq:NBSC), today announced that Arthur J. Blume, Ph.D., has been appointed to the additional position of chief executive officer of the Company's majority-owned DGI BioTechnologies LLC.Dr. Blume also serves as DGI's president and chief operating officer. Dr. Blume, 58, founded DGI in 1995 and is the developer of its proprietary Diogenesis® drug-lead-discovery process.He has more than 25 years of research and drug-discovery experience, including his tenure as chief operating officer of GeneLogic, Inc., and previous senior-level positions with Lederle Laboratories and the Roche Institute of Molecular Biology.From 1967 to 1971, Blume was a staff and post doctorate fellow with the National Institutes of Health, where he established and characterized the first neuronal tissue cultures.Dr. Blume earned his M.S. and Ph.D., Bacterial Genetics and Molecular Biology, (1963-68) from Syracuse University.
Said Dr. Blume: "This is an exciting time for DGI, which is anticipating an expansion this year of its collaborative effort with research partner Novo Nordisk.We have an excellent core scientific team in place, and we intend to develop that infrastructure as DGI continues to grow its intellectual property portfolio, accelerate and expand the number and scope of projects on which we are working, and seek additional strategic partners to enhance our development." He continued: "Another key initiative this year is aimed at improving our visibility in the scientific and financial communities via a more proactive communication program.
Thank You for Downloading!
1. Download ZoomInfo Grow
2. Run Installation Wizard
3. Check your inbox to Sign in to ZoomInfo Grow